JPMorgan Raises CG Oncology Price Target to $113
The target implies substantial upside, though analyst targets are opinions and the sharp recent decline is a caution.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The target implies substantial upside, though analyst targets are opinions and the sharp recent decline is a caution.
What happened, with direct paths to the underlying reporting
JPMorgan raised its CGON target to $113, about 33% above the posted price of $84.78. Shares were down 9.88% since the signal, adding near-term volatility to the bullish target-based view.
Target: $113
Posted price: $84.78
Analyst firm: J.P. Morgan
Analyst: Brian Cheng
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.